German pharmaceutical giant Bayer AG will invest more than $30 million over the next five years to create a lab at Brigham and Women’s Hospital to develop drugs to treat chronic lung diseases.
The lab in the Longwood Medical Area will employ about 20 scientists from Bayer, Brigham, and Massachusetts General Hospital. The three organizations will equally share the rights to any discoveries made as part of the venture.
“The invaluable expertise that BWH and MGH bring really complements our own strengths in drug discovery and development, making this collaboration particularly special,” said Dr. Joerg Moeller, an executive vice president of Bayer and head of global research and development.
